Overview

Webcast ImageWebcast
Q4 2017 T2 Biosystems Inc. Earnings Conference Call (Live)
03/06/18 at 4:30 p.m. ET
Q4 2017 T2 Biosystems Inc. Earnings Conference Call
Tuesday, March 6, 2018 4:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Corporate Profile

T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today. The T2Sepsis SolutionTM is a unique approach that combines the standard of care for the management of sepsis patients with T2 Biosystems’ products, including the T2Dx® Instrument and T2Candida® Panel, and the T2Bacteria® Panel, which is commercially available in Europe and other countries that accept the CE Mark and available for research use only in the U.S. Powered by the proprietary T2 Magnetic Resonance technology, or T2MR®, the T2Sepsis Solution is proven to deliver better patient care and greater cost savings. Hospital customer experience has demonstrated faster time to effective treatment, shortened ICU and hospital lengths of stay, reduced use of unnecessary antifungals, and millions of dollars in savings. T2 Biosystems has an active pipeline of future sepsis products including additional species and antibiotic resistance, as well as tests for Lyme disease and hemostasis. For more information, please visit  www.t2biosystems.com.
Stock Quote
TTOO (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$4.20
Change (%) Stock is Down 0.22 (4.98%)
Volume95,390
Data as of 02/22/18 3:03 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
DateTitle 
02/20/18T2 Biosystems Announces 2017 Fourth Quarter and Full-Year Financial and Operational Results Release and Conference Call Date
LEXINGTON, Mass., Feb. 20, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, today announced that it will release its 2017 fourth quarter and full-year financial and operational results after the market closes on Tuesday, March 6, 2018. In conjunction with the release, the Company will host a conference call with the investment community at 4:30... 
Printer Friendly Version
02/09/18Two New Studies Demonstrate T2Candida’s Advantages over Current Diagnostic Testing
Studies demonstrate T2Candida identifies infections missed by blood culture and the opportunity for faster targeted therapy LEXINGTON, Mass., Feb. 09, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development of innovative medical diagnostic products for critical unmet needs in healthcare, is announcing the release of two new peer-reviewed publications that demonstrate the superior performance of the T2Candida® Panel over blood culture and the capability of the T... 
Printer Friendly Version
02/06/18T2 Biosystems to Present at the 7th Annual Leerink Partners Global Healthcare Conference
LEXINGTON, Mass., Feb. 06, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the development of innovative medical diagnostic products for critical unmet needs in healthcare, today announced that John McDonough, president and chief executive officer is scheduled to present at the 7th Annual Leerink Partners Global Healthcare Conference.  The conference is being held February 14-15 at the Lotte New York Palace Hotel in New York.   The Company is scheduled to present on T... 
Printer Friendly Version
02/05/18T2 Biosystems Announces CFO Transition
LEXINGTON, Mass., Feb. 05, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the development of innovative medical diagnostic products for critical unmet needs in healthcare, today announced that John Sprague has been named chief financial officer. Mr. Sprague is a highly accomplished financial executive who brings an extensive array of financial experience to T2 Biosystems, including a demonstrated success and leadership in building out companies during high-growth per... 
Printer Friendly Version

More News

Investor Contact Information
Contact: ir@T2Biosystems.com
(781) 761-4646

Chris Brinzey, Westwicke Partners chris.brinzey@westwicke.com
(339) 970-2843

Data provided by Nasdaq. Minimum 15 minutes delayed.